Phaseline

Companies › Grace Therapeutics

Grace Therapeutics: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 3; Cardiovascular.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
GTX-104
Nimodipine IV infusion - dihydropyridine calcium channel blocker
Ion channelsPhase 3Aneurysmal Subarachnoid Hemorrhage (aSAH)–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05995405GTX-104Phase 3Aneurysmal Subarachnoid Hemorrhage (aSAH)CardiovascularDec 2024

From the company's SEC filings

Cash of $14m on 2026-06-30; operating cash outflow about $13m a year; runway about 13 months at that burn, to Jul 2027

Press releases filed as 8-K in the last year:

Regulatory dates the company has stated

Private offerings reported to the SEC (Form D)

Targets

Ion channels (1)

Companies with the same targets

Xenon Pharmaceuticals Praxis Precision Medicines HB BioTech Encoded Therapeutics Biohaven Therapeutics TLC Biopharmaceuticals Shenzhen Ausa Pharmed LXO Ireland Jiangsu HengRui Medicine Industrial Farmacéutica Cantabria

Companies built like this

Shenzhen Ausa Pharmed Braveheart Bio Gossamer Bio USA Mineralys Therapeutics CeleCor Therapeutics

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.